Impact of dedicated brain PET on intended patient management in participants of the national oncologic PET Registry

Bruce E Hillner, Barry A Siegel, Anthony F Shields, Fenghai Duan, Ilana F Gareen, Lucy Hanna, R Edward Coleman, Bruce E Hillner, Barry A Siegel, Anthony F Shields, Fenghai Duan, Ilana F Gareen, Lucy Hanna, R Edward Coleman

Abstract

Purpose: This study seeks to assess the impact of dedicated brain positron emission tomography (PET) with 2-deoxy-2-[(18)F]fluoro-D-glucose on intended management of patients with primary and metastatic brain tumors.

Procedures: We analyzed demographic characteristics and evaluated change in intended management after PET, using previously described metrics, for patients in the National Oncologic PET Registry (NOPR) undergoing dedicated brain PET. For cases of primary brain tumors, comparisons to the overall NOPR cohort were made. PATIENT PROFILE: Between December 2006 and April 2009, 509 dedicated brain PET scans were done on 479 patients--367 (72.1%) for suspected or proven primary brain tumors and 142 (27.9%) for brain metastases. Compared with the overall NOPR cohort, subjects in the dedicated brain cohort were younger (41.3% less than 65 years vs. 10.5% overall, p < 0.0001) and more frequently had functional limitations from their cancers (78.6% vs. 62.3% overall; odds ratio (OR) 2.2, 95% CI 1.8-2.8).

Results: The pre-PET patient management plans in the primary brain tumor and metastasis subgroups were similar. A pre-PET plan of tissue biopsy was slightly more frequent than one of the treatments (31.3% vs. 28.6%) in the primary brain tumor subgroup and was more common than in the overall NOPR cohort (14.2%; OR 2.8, 95% CI 2.2-3.5). Changes from treatment to non-treatment also were more frequent than in the overall NOPR cohort (13.4% vs. 7.7%; OR 1.9, 95% CI 1.3-2.5).

Conclusions: Among NOPR patients, dedicated brain PET was associated with similar net changes in intended management as in the overall NOPR cohort. However, brain PET patients were younger, more likely to be symptomatic, and less likely to have a change in management from non-treatment to treatment as a post-PET plan.

References

    1. NCCN clinical practice guidelines in oncology. Central nervous system cancers. V.1.2010., 2010. (Accessed at . Accessed June 1, 2010)
    1. Fischman AJ. PET imaging of brain tumors. Cancer Treat Res. 2008;143:67–92. doi: 10.1007/978-0-387-75587-8_3.
    1. Chen W. Clinical applications of PET in brain tumors. J Nucl Med. 2007;48:1468–1481. doi: 10.2967/jnumed.106.037689.
    1. Hustinx R, Pourdehnad M, Kaschten B, Alavi A. PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am. 2005;43:35–47. doi: 10.1016/j.rcl.2004.09.009.
    1. Centers for Medicare & Medicaid Services. Pub 100-03 Medicare National Coverage Determinations. Transmittal 31. 2005
    1. Tunis S, Whicher D. The National Oncologic PET Registry: lessons learned for coverage with evidence development. J Am Coll Radiol. 2009;6:360–365. doi: 10.1016/j.jacr.2009.01.016.
    1. Tunis SR, Pearson SD. Coverage options for promising technologies: Medicare’s ‘coverage with evidence development’. Health Aff. 2006;25:1218–1230. doi: 10.1377/hlthaff.25.5.1218.
    1. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol. 2008;26:2155–2161. doi: 10.1200/JCO.2007.14.5631.
    1. Hillner BE, Siegel BA, Shields AF, et al. Relationship between cancer type and impact of PET and PET/CT on intended management: findings of the National Oncologic PET Registry. J Nucl Med. 2008;49:1928–1935. doi: 10.2967/jnumed.108.056713.
    1. Hillner BE, Liu D, Coleman RE, et al. The National Oncologic PET Registry (NOPR): design and analysis plan. J Nucl Med. 2007;48:1901–1908. doi: 10.2967/jnumed.107.043687.
    1. Cha S. Neuroimaging in neuro-oncology. Neurotherapeutics. 2009;6:465–477. doi: 10.1016/j.nurt.2009.05.002.
    1. Physician Data Query. National Cancer Institute. Adult Brain Tumors Treatment (Accessed at on July 9, 2010)
    1. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology. 1993;186:37–44.
    1. Rohren EM, Provenzale JM, Barboriak DP, Coleman RE. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology. 2003;226:181–187. doi: 10.1148/radiol.2261010920.
    1. National Program of Cancer Registries (NPCR), Centers for Disease Control and Prevention, Department of Health and Human Services. United States Cancer Statistics (USCS): 1999–2006 Cancer Incidence and Mortality Data. Available at: . Accessed August 11, 2010

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir